Misonix Incorporated (NASDAQ:MSON) had a decrease of 2.18% in short interest. MSON’s SI was 22,400 shares in January as released by FINRA. Its down 2.18% from 22,900 shares previously. With 5,700 avg volume, 4 days are for Misonix Incorporated (NASDAQ:MSON)’s short sellers to cover MSON’s short positions. The SI to Misonix Incorporated’s float is 0.36%. The stock increased 0.56% or $0.05 during the last trading session, reaching $9.05. About 3,978 shares traded. Misonix, Inc. (NASDAQ:MSON) has risen 145.17% since January 27, 2017 and is uptrending. It has outperformed by 128.47% the S&P500.
Analysts expect Blue Bird Corporation (NASDAQ:BLBD) to report $0.01 EPS on February, 8.They anticipate $0.14 EPS change or 107.69% from last quarter’s $-0.13 EPS. BLBD’s profit would be $239,643 giving it 518.75 P/E if the $0.01 EPS is correct. After having $0.50 EPS previously, Blue Bird Corporation’s analysts see -98.00% EPS growth. The stock increased 2.98% or $0.6 during the last trading session, reaching $20.75. About 144,525 shares traded or 159.67% up from the average. Blue Bird Corporation (NASDAQ:BLBD) has risen 78.78% since January 27, 2017 and is uptrending. It has outperformed by 62.08% the S&P500.
Misonix, Inc., together with its subsidiaries, designs, develops, makes, and markets therapeutic ultrasonic medical devices in the United States and internationally. The company has market cap of $84.76 million. The firm offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells, as well as other medical devices. It currently has negative earnings. The Company’s products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, plastic surgery, wounds, and maxillo-facial applications.
Investors sentiment decreased to 0.57 in 2017 Q3. Its down 0.14, from 0.71 in 2017Q2. It dived, as 1 investors sold Misonix, Inc. shares while 6 reduced holdings. 2 funds opened positions while 2 raised stakes. 948,491 shares or 0.37% less from 951,978 shares in 2017Q2 were reported. Deutsche Bank Ag holds 0% or 300 shares. Rathbone Brothers Plc invested in 0.01% or 14,600 shares. 435,707 were reported by Dimensional Fund Advisors L P. Renaissance Technology Limited Liability Company invested 0% of its portfolio in Misonix, Inc. (NASDAQ:MSON). Wealthtrust Axiom Ltd Liability Corp owns 0.27% invested in Misonix, Inc. (NASDAQ:MSON) for 70,345 shares. Vanguard Gp stated it has 0% of its portfolio in Misonix, Inc. (NASDAQ:MSON). Morgan Stanley accumulated 4,500 shares or 0% of the stock. Blackrock Inc has 17,828 shares. Commercial Bank Of America Corp De has invested 0% in Misonix, Inc. (NASDAQ:MSON). Royal Natl Bank Of Canada owns 1 shares. Northern Tru Corp has 0% invested in Misonix, Inc. (NASDAQ:MSON) for 23,578 shares. Bridgeway Capital accumulated 54,800 shares or 0.01% of the stock. Geode Capital Mgmt owns 30,511 shares.
Among 4 analysts covering Blue Bird Corporation (NASDAQ:BLBD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Blue Bird Corporation had 9 analyst reports since September 16, 2015 according to SRatingsIntel. Stifel Nicolaus maintained the stock with “Buy” rating in Monday, September 11 report. Roth Capital maintained the stock with “Buy” rating in Monday, August 7 report. Roth Capital initiated the stock with “Buy” rating in Friday, December 16 report. Craig Hallum initiated it with “Buy” rating and $14 target in Monday, March 7 report. Stifel Nicolaus maintained it with “Buy” rating and $21.0 target in Thursday, December 7 report. The firm has “Buy” rating by Craig Hallum given on Friday, August 5. The firm has “Buy” rating given on Monday, July 17 by Stifel Nicolaus. The firm has “Outperform” rating by BMO Capital Markets given on Wednesday, September 16.
Blue Bird Corporation designs, engineers, makes, and sells school buses and aftermarket parts in the United States, Canada, and internationally. The company has market cap of $497.26 million. The firm operates through two divisions, Buses and Aftermarket Parts. It has a 27.96 P/E ratio. It offers Type C, Type D, and specialty buses, as well as Sigma, a bus for public transportation.